Companies › NAUT

NAUTILUS BIOTECHNOLOGY INC (NAUT)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001808805 · EDGAR filings · Updated 2026-07-28

NAUTILUS BIOTECHNOLOGY INC (NAUT) has reported institutional ownership of 42.7%, with 81 institutional managers holding positions valued at $210.8M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (2)

• 2026-07-28 — Quarterly report (10-Q) filed
• 2026-07-28 — Current report (8-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-06-30 — SCHEDULE 13D/A filed
• 2026-06-22 — Insider transaction reported (Form 4)
• 2026-06-22 — Insider transaction reported (Form 4)
• 2026-06-22 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, NAUTILUS BIOTECHNOLOGY INC has 81 institutional holders and institutional ownership of 42.7%.

Insider activity

Insiders reported 8 transactions (8 buys, 0 sells) across 5 reporting insiders, with a net reported value of $240.2K.

Data flags from SEC filings

Related companies

ALTIMMUNE INC (ALT) · CANDEL THERAPEUTICS INC (CADL) · FOGHORN THERAPEUTICS INC (FHTX) · KEROS THERAPEUTICS INC (KROS) · OPUS GENETICS INC (IRD) · OCUGEN INC COM (OCGN)